Tripeptide-29
Tripeptide-29 is a collagen-fragment tripeptide and GHK analogue that stimulates procollagen I synthesis and promotes wound healing by mimicking a type I collagen signaling fragment to activate dermal fibroblasts.
Tripeptide-29 is a synthetic peptide based on a fragment of type I collagen that functions as a matrikine -- a bioactive peptide derived from extracellular matrix proteins that signals cells to modulate matrix synthesis. As a GHK (glycyl-histidyl-lysine) structural analogue, Tripeptide-29 stimulates dermal fibroblasts to increase procollagen I synthesis and promotes wound healing processes.
Overview
Collagen type I is the most abundant structural protein in human skin, comprising approximately 80% of dermal dry weight. Its production declines at approximately 1-1.5% per year after age 25, leading to progressive skin thinning, wrinkle formation, and impaired wound healing capacity. The body naturally regulates collagen synthesis through feedback mechanisms involving matrikines -- peptide fragments released during collagen turnover that signal fibroblasts to produce replacement collagen.
Tripeptide-29 exploits this natural feedback mechanism by providing an exogenous matrikine signal. The peptide's sequence is derived from the collagen I molecule and shares structural similarity with GHK (glycyl-histidyl-lysine), one of the most studied naturally occurring matrikines. Like GHK, Tripeptide-29 activates fibroblast receptors involved in matrix remodeling, but its modified sequence provides distinct binding characteristics and potentially enhanced stability.
The peptide is used in cosmetic formulations targeting both anti-aging applications (restoring age-related collagen decline) and wound healing support (accelerating post-procedural skin recovery). It is typically formulated at low concentrations in serums, creams, and post-procedure recovery products.
Mechanism of Action
Tripeptide-29 functions through the matrikine signaling pathway. When collagen is degraded during normal turnover or tissue remodeling, specific peptide fragments are released that act as signals to surrounding fibroblasts. These fragments bind to cell-surface receptors and activate intracellular pathways that upregulate procollagen gene expression.
Tripeptide-29 mimics this degradation-derived signal, binding to fibroblast receptors and activating the TGF-beta and Smad signaling pathways that drive procollagen I transcription. The activated fibroblasts increase production of procollagen I alpha chains, which are processed, secreted, and assembled into mature collagen fibrils in the extracellular space.
As a GHK analogue, the peptide shares the ability to modulate multiple genes involved in tissue repair. GHK itself has been shown to influence the expression of over 4,000 human genes, including upregulation of collagen synthesis genes and downregulation of metalloproteinase genes that degrade existing collagen. Tripeptide-29 engages a subset of these pathways with a focus on procollagen I production.
In wound healing contexts, the peptide accelerates the proliferative phase by stimulating fibroblast migration, proliferation, and matrix deposition. This supports faster wound closure and improved scar quality by ensuring adequate collagen deposition during the repair process.
Research
Wound Healing Applications
The peptide has been evaluated for its potential to support wound healing, particularly in the context of post-procedural skin recovery. In scratch-wound assays using fibroblast monolayers, Tripeptide-29 accelerated wound closure compared to controls. The accelerated healing was attributed to both increased fibroblast migration into the wound area and enhanced matrix deposition at the wound margins.
Procollagen I Synthesis
In vitro studies using human dermal fibroblast cultures demonstrated that Tripeptide-29 significantly increases procollagen I secretion in a dose-dependent manner. ELISA quantification of procollagen I C-terminal propeptide (PICP) in culture supernatants showed increases of 30-50% above untreated controls at optimal concentrations. Gene expression analysis confirmed upregulation of COL1A1 and COL1A2 mRNA levels.
Comparison with GHK-Cu
While structurally related to the GHK motif, Tripeptide-29 differs from GHK-Cu in several respects. GHK-Cu is a copper-binding tripeptide with broad biological activity spanning collagen synthesis, anti-inflammatory effects, and stem cell recruitment. Tripeptide-29 has a more focused activity profile centered on procollagen I synthesis without requiring copper complexation. This makes it suitable for formulations where copper inclusion is undesirable or where a more targeted collagen-stimulating effect is preferred.
Anti-Aging Formulation Performance
Clinical evaluation of formulations containing Tripeptide-29 demonstrated improvements in skin firmness, thickness, and wrinkle depth over 8-12 week treatment periods. Ultrasound measurement of dermal thickness showed increases consistent with new collagen deposition. The improvements were gradual, consistent with the time required for de novo collagen synthesis and maturation (6-12 weeks for collagen cross-linking and fibril organization).
Safety Profile
Tripeptide-29 has a favorable safety profile for topical cosmetic and cosmeceutical use. As a fragment of endogenous human collagen, the peptide has excellent biocompatibility. Dermatological testing shows no irritation, sensitization, or phototoxicity at recommended concentrations. The peptide is compatible with sensitive and post-procedural skin. Systemic absorption from topical application is negligible due to the peptide's hydrophilicity and molecular size. No adverse effects have been reported in published studies.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Route
- Topical
Molecular Structure
- Formula
- C₁₅H₂₅N₅O₅ (approximate)
- Weight
- 285.30 Da
- CAS
- 75644-68-3
- PubChem CID
- 11778669
- Exact Mass
- 285.1325 Da
- LogP
- -4.3
- TPSA
- 124 Ų
- H-Bond Donors
- 3
- H-Bond Acceptors
- 6
- Rotatable Bonds
- 3
- Complexity
- 427
Identifiers (SMILES, InChI)
InChI=1S/C12H19N3O5/c13-5-10(17)14-3-1-2-8(14)11(18)15-6-7(16)4-9(15)12(19)20/h7-9,16H,1-6,13H2,(H,19,20)/t7-,8+,9+/m1/s1
SZEOBSAZWJLOGY-VGMNWLOBSA-NResearch Protocols
topical
Safety Profile Tripeptide-29 has a favorable safety profile for topical cosmetic and cosmeceutical use. Systemic absorption from topical application is negligible due to the peptide's hydrophilicity and molecular size.
Interactions
Peptide Interactions
While structurally related to the GHK motif, Tripeptide-29 differs from GHK-Cu in several respects. GHK-Cu is a copper-binding tripeptide with broad biological activity spanning collagen synthesis, anti-inflammatory effects, and stem cell recruitment. Tripeptide-29 has a more focused activity pro...
Quality Indicators
What to look for
- Well-established safety profile
- Naturally occurring compound
Frequently Asked Questions
References (6)
- [5]
- [6]
- [7]
- [3]Lintner K et al Cosmetic peptides Int J Cosmet Sci (2009)
- [1]Katayama K et al A pentapeptide from type I procollagen promotes extracellular matrix production J Biol Chem (1993)
- [2]Pickart L et al GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration BioMed Res Int (2015)
Tripeptide-10 Citrulline
Tripeptide-10 Citrulline (Decorinyl) is a Lipotec-developed peptide that stimulates decorin production to regulate collagen fibrillogenesis, improving extracellular matrix organization and reducing wrinkle depth.
Triptorelin
Triptorelin is a synthetic GnRH agonist (D-Trp6-GnRH) used clinically for prostate cancer, endometriosis, precocious puberty, and uterine fibroids. Available as 1-, 3-, and 6-month depot formulations, it achieves sustained gonadotropin suppression through GnRH receptor desensitization after an initial hormonal flare.